Skip to content

Sandoz Group AG

🇬🇧XLON.0SANUnited KingdomHealthcare

£71.04GBPup +0.16 (+0.23%)ClosedEnd of day2:00 PM

Price£71.04+0.16 (+0.23%)

Latest anomalies

Positive 7 detected in the last 120 days

  • High: 1
  • Medium: 2
  • Low: 4
  • Overnight gap: a gap up from the prior close

    Price Low

  • 52-week high: the price is trading close to this level

    Price Low

  • Daily return: an extreme move up, far outside its trailing 60-day range

    Price High

  • Overnight gap: a gap up from the prior close

    Price Low

  • Volume: a spike above the 20-day average

    Price Medium

View all anomalies

Free with a Finzer account.

Profile

  • Healthcare
  • Drug Manufacturers - Specialty & Generic
  • United Kingdom

Identity

Type
Stock
ISIN
CH1243598427
CUSIP
Not reported

Company

Employees
20,000
Headquarters
Basel, Switzerland

Market

Shares outstanding
0
Market cap
£27.93B

Highlights

Day range£70.14 - £71.16
today's session
52-week range£44.01 - £75.90
from 248 sessions
Market cap
£27.93B
EPS LTM
CHF 0.18
P/E LTM
Not reported
Div yield
Not reported

Fundamentals (LTM)

Revenue
CHF 12.24B-9.88%down year on year
Net income
CHF 79.55M-90.98%down year on year
Gross margin
45.63%-3.6%down year on year
Free cash flow
CHF 198M-79.94%down year on year

View all financials

Latest news

News is not sourced for this exchange.

Business summary

Sandoz Group AG is a company in the healthcare sector, listed on London Stock Exchange (United Kingdom) under the ticker 0SAN. Its market capitalisation is £27.93B, as of . Across the 248 trading sessions to the shares traded between £44.01 and £75.90, and the last close of £71.04 sits 85% of the way up that range. The company is headquartered in Basel, Switzerland, and employs about 20,000 people. This is the London Stock Exchange listing of Sandoz Group AG; its primary listing is SDZ on SIX Swiss Exchange.

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.